Tag Archive for: mRNA

Versameb AG Names Dr. Alexandre LeBeaut as Chair of the Board of Directors

PRESS RELEASE | Basel, Switzerland, December 5, 2023

Versameb AG (“Versameb”), a pre-clinical stage company focused on transforming RNA therapeutics to treat unmet medical needs, today announced that its Board of Directors has unanimously appointed of Dr. Alexandre LeBeaut, MD as Chairman of the Board, effective immediately. Dr. LeBeaut has over two decades of global R&D leadership experiences, successfully bringing multiple medicines to market in immunology, oncology, gastroenterology, cardio-metabolic and infectious diseases.

Read more

Versameb AG Announces FDA Clearance of IND Application for VMB-100 in the Treatment of Stress Urinary Incontinence

PRESS RELEASE | Basel, Switzerland, November 16, 2023

Versameb AG (“Versameb”), a pre-clinical stage company focused on transforming RNA therapeutics to treat unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application of VMB-100, a potency enhanced messenger ribonucleic acid (mRNA) encoding human insulin-like growth factor-1 (IGF-1), for the treatment of stress urinary incontinence (SUI).

Read more

Versameb Strengthens its Board of Directors

PRESS RELEASE | Basel, Switzerland, July 10, 2023

Versameb AG (“Versameb”), transforming (m)RNA therapeutics to cure hard-to-treat and/or prevalent diseases, is pleased to announce the appointments of Hernán Levett, Dr Lily Geidelberg, Paul Korner, MD, MBA and Dr Alexandre LeBeaut to its board of directors as it prepares to enter clinical development with lead candidate, VMB-100, an RNA-based therapy for the treatment of Stress Urinary Incontinence (SUI).

Read more

Versameb Appoints Professor Roger Dmochowski as Chief Medical Officer

PRESS RELEASE | Basel, Switzerland, June 21, 2023

Versameb AG (“Versameb”), a pre-clinical stage company focused on discovering and developing innovative RNA-based therapeutics, is pleased to announce the appointment of Professor Roger Dmochowski as Chief Medical Officer with immediate effect.

Read more

Versameb Chief Executive Officer to Present at LSX Inv€$tival Showcase Conference

PRESS RELEASE | Basel, Switzerland, November 10, 2022

Versameb AG (“Versameb”), a pre-clinical stage company focused on discovering and developing innovative RNA-based therapeutics, is pleased to announce that its Chief Executive Officer, Klaas Zuideveld will be presenting on the Company’s proprietary mRNA engineering technology platform, VERSagile, at the LSX Inv€$tival Showcase Conference taking place on 14 November 2022 at Old Billingsgate in London, UK.

Read more

Versameb to present at the BIO Asia-Taiwan Conference

PRESS RELEASE | Basel, Switzerland, July 22, 2022

Versameb AG (“Versameb”), a pre-clinical stage company focused on discovering and developing innovative RNA-based therapeutics, today announces that its Chief Executive Officer, Klaas Zuideveld will be presenting on the Company’s mRNA engineering technology platform VERSagile and lead therapeutic candidate VMB-100 at the BIO Asia-Taiwan Conference, taking place on 27-31 July 2022 in Taiwan.

Read more

Versameb to Present during World Continence Week 2022

PRESS RELEASE | Basel, Switzerland, June 20, 2022

Versameb AG (“Versameb”), focused on discovering and developing innovative RNA-based drugs, is pleased to announce that Chief Executive Officer Klaas Zuideveld and Clinical Advisor Prof. Roger Dmochowski will be presenting Versameb’s lead therapeutic candidate, VMB-100, for the treatment of Stress Urinary Incontinence (SUI) at World Continence Week (WCW) 20-26 June 2022. WCW is an annual initiative fully endorsed by the European Association of Urology (EAU) and the International Continence Society (ICS) set up by the World Federation of Incontinence and Pelvic Problems (WFIPP) to raise awareness of bladder & bowel issues, chronic pelvic pain and other debilitating conditions which impact the lives of millions of patients worldwide.

Read more

Versameb to Present at the 2022 American Association for Cancer Research (AACR) Annual Meeting

PRESS RELEASE | Basel, Switzerland, April 5, 2022

Versameb AG (“Versameb”), focused on discovering and developing innovative RNA-based drugs, today announces it will present a poster entitled ‘Design of combinatory RNA molecules to simultaneously activate tumor immunity and target several signaling pathways in solid tumors’ on the 11th of April at the American Association of Cancer Research (AACR) Annual Meeting, taking place in New Orleans, USA on the 8 – 13 April 2022.

Read more

Versameb CEO Klaas Zuideveld to Present at the RNA Leaders World Congress

PRESS RELEASE | Basel, Switzerland, March 10, 2022

Versameb AG (“Versameb”), a pre-clinical stage company focused on discovering and developing innovative RNA-based therapeutics, today announces that its leadership team will be attending the RNA Leaders World Congress, taking place on the 16-17th March 2022 in Basel, Switzerland, where Chief Executive Officer Klaas Zuideveld will be presenting data on the Company’s mRNA engineering technology and its lead therapeutic candidate, VMB-100.

Read more

Touchlight and Versameb announce GMP manufacturing supply agreement

PRESS RELEASE | Hampton, UK / Basel, Switzerland, March 01, 2022

Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, today announces a development and manufacturing pipeline agreement with Versameb AG, an innovative pre-clinical stage company focused on discovering and developing ground-breaking RNA-based therapeutics.

Read more